Pseudocarcinomatous urothelial hyperplasia of the bladder: Clinical findings and followup of 70 patients

Oleksandr N. Kryvenko, Jonathan Ira Epstein

Research output: Contribution to journalArticle

Abstract

Purpose: Pseudocarcinomatous urothelial hyperplasia is rare and almost exclusively described in the pathology literature. Materials and Methods: We reviewed 70 cases during a 9.5-year period. Results: Two specimens were taken from biopsies done at our institution and 68 were from cases referred for consultation. Samples were obtained from a total of 60 men and 10 women with a mean age of 67 years (range 33 to 85). Of 68 patients with information available 52 (76.5%) underwent prior pelvic irradiation, 2 received systemic chemotherapy only, 3 had an indwelling bladder catheter, 2 received intravesical chemotherapy, 1 had been treated with radical prostatectomy, 4 had severe peripheral vascular disease, 1 had an arteriovenous malformation, 1 had sickle cell disease and only 2 (2.9%) had no identifiable contributing factors. Pseudocarcinomatous urothelial hyperplasia developed an average of 54.6 months (range 9 months to 13 years) after prior irradiation. Hematuria was the most common clinical presentation, noted in 45 of 51 patients with data available. Of 48 patients with data endoscopy revealed erythema in 20, a papillary/polypoid lesion in 12, broad-based elevated erythematous lesions in 6, erythematous bullous edema in 5, shallow bleeding ulcers in 4 and prominent trabeculation in 1. Additional findings in the bladder were carcinoma in situ in 3 cases, and dysplasia, low grade papillary urothelial carcinoma and papillary urothelial hyperplasia in 1 each. Three of the 40 patients with an average followup of 27 months (range 1 to 94) subsequently had urothelial carcinoma, including 1 who had prior positive cytology and fluorescence in situ hybridization, 1 with prior high grade papillary urothelial carcinoma and 1 with an unknown history. Conclusions: Although pseudocarcinomatous urothelial hyperplasia mimics invasive urothelial carcinoma clinically and histologically, it is not related to urothelial neoplasms. Almost all patients have causes of bladder ischemia, most commonly a history of remote prior pelvic irradiation.

Original languageEnglish (US)
Pages (from-to)2083-2086
Number of pages4
JournalJournal of Urology
Volume189
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Hyperplasia
Urinary Bladder
Papillary Carcinoma
Carcinoma
Drug Therapy
Indwelling Catheters
Peripheral Vascular Diseases
Arteriovenous Malformations
Carcinoma in Situ
Sickle Cell Anemia
Hematuria
Erythema
Prostatectomy
Fluorescence In Situ Hybridization
Endoscopy
Ulcer
Cell Biology
Edema
Referral and Consultation
Ischemia

Keywords

  • hyperplasia
  • ischemia
  • radiotherapy
  • urinary bladder
  • urothelium

ASJC Scopus subject areas

  • Urology

Cite this

Pseudocarcinomatous urothelial hyperplasia of the bladder : Clinical findings and followup of 70 patients. / Kryvenko, Oleksandr N.; Epstein, Jonathan Ira.

In: Journal of Urology, Vol. 189, No. 6, 06.2013, p. 2083-2086.

Research output: Contribution to journalArticle

@article{e22ad530fb274b399da2746fec100920,
title = "Pseudocarcinomatous urothelial hyperplasia of the bladder: Clinical findings and followup of 70 patients",
abstract = "Purpose: Pseudocarcinomatous urothelial hyperplasia is rare and almost exclusively described in the pathology literature. Materials and Methods: We reviewed 70 cases during a 9.5-year period. Results: Two specimens were taken from biopsies done at our institution and 68 were from cases referred for consultation. Samples were obtained from a total of 60 men and 10 women with a mean age of 67 years (range 33 to 85). Of 68 patients with information available 52 (76.5{\%}) underwent prior pelvic irradiation, 2 received systemic chemotherapy only, 3 had an indwelling bladder catheter, 2 received intravesical chemotherapy, 1 had been treated with radical prostatectomy, 4 had severe peripheral vascular disease, 1 had an arteriovenous malformation, 1 had sickle cell disease and only 2 (2.9{\%}) had no identifiable contributing factors. Pseudocarcinomatous urothelial hyperplasia developed an average of 54.6 months (range 9 months to 13 years) after prior irradiation. Hematuria was the most common clinical presentation, noted in 45 of 51 patients with data available. Of 48 patients with data endoscopy revealed erythema in 20, a papillary/polypoid lesion in 12, broad-based elevated erythematous lesions in 6, erythematous bullous edema in 5, shallow bleeding ulcers in 4 and prominent trabeculation in 1. Additional findings in the bladder were carcinoma in situ in 3 cases, and dysplasia, low grade papillary urothelial carcinoma and papillary urothelial hyperplasia in 1 each. Three of the 40 patients with an average followup of 27 months (range 1 to 94) subsequently had urothelial carcinoma, including 1 who had prior positive cytology and fluorescence in situ hybridization, 1 with prior high grade papillary urothelial carcinoma and 1 with an unknown history. Conclusions: Although pseudocarcinomatous urothelial hyperplasia mimics invasive urothelial carcinoma clinically and histologically, it is not related to urothelial neoplasms. Almost all patients have causes of bladder ischemia, most commonly a history of remote prior pelvic irradiation.",
keywords = "hyperplasia, ischemia, radiotherapy, urinary bladder, urothelium",
author = "Kryvenko, {Oleksandr N.} and Epstein, {Jonathan Ira}",
year = "2013",
month = "6",
doi = "10.1016/j.juro.2012.12.005",
language = "English (US)",
volume = "189",
pages = "2083--2086",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pseudocarcinomatous urothelial hyperplasia of the bladder

T2 - Clinical findings and followup of 70 patients

AU - Kryvenko, Oleksandr N.

AU - Epstein, Jonathan Ira

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: Pseudocarcinomatous urothelial hyperplasia is rare and almost exclusively described in the pathology literature. Materials and Methods: We reviewed 70 cases during a 9.5-year period. Results: Two specimens were taken from biopsies done at our institution and 68 were from cases referred for consultation. Samples were obtained from a total of 60 men and 10 women with a mean age of 67 years (range 33 to 85). Of 68 patients with information available 52 (76.5%) underwent prior pelvic irradiation, 2 received systemic chemotherapy only, 3 had an indwelling bladder catheter, 2 received intravesical chemotherapy, 1 had been treated with radical prostatectomy, 4 had severe peripheral vascular disease, 1 had an arteriovenous malformation, 1 had sickle cell disease and only 2 (2.9%) had no identifiable contributing factors. Pseudocarcinomatous urothelial hyperplasia developed an average of 54.6 months (range 9 months to 13 years) after prior irradiation. Hematuria was the most common clinical presentation, noted in 45 of 51 patients with data available. Of 48 patients with data endoscopy revealed erythema in 20, a papillary/polypoid lesion in 12, broad-based elevated erythematous lesions in 6, erythematous bullous edema in 5, shallow bleeding ulcers in 4 and prominent trabeculation in 1. Additional findings in the bladder were carcinoma in situ in 3 cases, and dysplasia, low grade papillary urothelial carcinoma and papillary urothelial hyperplasia in 1 each. Three of the 40 patients with an average followup of 27 months (range 1 to 94) subsequently had urothelial carcinoma, including 1 who had prior positive cytology and fluorescence in situ hybridization, 1 with prior high grade papillary urothelial carcinoma and 1 with an unknown history. Conclusions: Although pseudocarcinomatous urothelial hyperplasia mimics invasive urothelial carcinoma clinically and histologically, it is not related to urothelial neoplasms. Almost all patients have causes of bladder ischemia, most commonly a history of remote prior pelvic irradiation.

AB - Purpose: Pseudocarcinomatous urothelial hyperplasia is rare and almost exclusively described in the pathology literature. Materials and Methods: We reviewed 70 cases during a 9.5-year period. Results: Two specimens were taken from biopsies done at our institution and 68 were from cases referred for consultation. Samples were obtained from a total of 60 men and 10 women with a mean age of 67 years (range 33 to 85). Of 68 patients with information available 52 (76.5%) underwent prior pelvic irradiation, 2 received systemic chemotherapy only, 3 had an indwelling bladder catheter, 2 received intravesical chemotherapy, 1 had been treated with radical prostatectomy, 4 had severe peripheral vascular disease, 1 had an arteriovenous malformation, 1 had sickle cell disease and only 2 (2.9%) had no identifiable contributing factors. Pseudocarcinomatous urothelial hyperplasia developed an average of 54.6 months (range 9 months to 13 years) after prior irradiation. Hematuria was the most common clinical presentation, noted in 45 of 51 patients with data available. Of 48 patients with data endoscopy revealed erythema in 20, a papillary/polypoid lesion in 12, broad-based elevated erythematous lesions in 6, erythematous bullous edema in 5, shallow bleeding ulcers in 4 and prominent trabeculation in 1. Additional findings in the bladder were carcinoma in situ in 3 cases, and dysplasia, low grade papillary urothelial carcinoma and papillary urothelial hyperplasia in 1 each. Three of the 40 patients with an average followup of 27 months (range 1 to 94) subsequently had urothelial carcinoma, including 1 who had prior positive cytology and fluorescence in situ hybridization, 1 with prior high grade papillary urothelial carcinoma and 1 with an unknown history. Conclusions: Although pseudocarcinomatous urothelial hyperplasia mimics invasive urothelial carcinoma clinically and histologically, it is not related to urothelial neoplasms. Almost all patients have causes of bladder ischemia, most commonly a history of remote prior pelvic irradiation.

KW - hyperplasia

KW - ischemia

KW - radiotherapy

KW - urinary bladder

KW - urothelium

UR - http://www.scopus.com/inward/record.url?scp=84877596245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877596245&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.12.005

DO - 10.1016/j.juro.2012.12.005

M3 - Article

C2 - 23228381

AN - SCOPUS:84877596245

VL - 189

SP - 2083

EP - 2086

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -